Conference abstract · 10 Mar 2016
Conference abstractPublished 7 Dec 2015
Rational Design Of Immune Checkpoints’ Small Molecule Inhibitors
University of Alberta, Canada
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
T lymphocytes preserve the immunological balance between defending against viral infection and preventing continual activated immune responses. While T cells’ specificity against cancer or viral infection is determined by the interaction between the T-cell receptor complex (TCR) and antigenic peptides bound in surface major histocompatibility complex (MHC) molecules, the full activation of T cells requires a second signal obtained by the binding of the co-receptor CD28 on T cells to CD80/86 molecules on activated antigen presenting cells (APCs). Once mobilized, T cells also express other receptors that inhibit their proliferation and cytokine production, known as immune checkpoints. Among these receptors are Cytotoxic T Lymphocyte Antigen-4 (CTLA-4), programmed death-1 (PD-1) and T cell immunoglobulin mucin-3 (TIM-3) and many others. Blocking the interactions between these receptors and their ligands emerged as a ‘game changer’ in immunotherapy, with antibodies directed toward PD-1, for example, being selected as ‘drug of the year’ for 2013 by Science. More importantly, combination blockage of multiple co-inhibitory pathways has a greater efficacy by preventing accumulation of the unblocked negative co-receptor, allowing T cells to continue to survive, proliferate, and carry out effector functions within infected cells. This talk will focus on PD-1 and will describe for the first time two accurate models for human PD-1 bound to its two human ligands. The talk will also demonstrate how these two models are being used to rationally design small molecule inhibitors for the Pd-1 pathway.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 2017
Rational design of small molecule immune checkpoints' inhibitors: The PD-1 challenge
Review article · 8 Apr 2022
The Application and Progress of Immune Checkpoint Inhibitors in the Immunotherapy of Non-Small Cell Lung Cancer
Case report · 28 Mar 2022
A case report and review of the literature of immune checkpoint inhibitor in a patient with small-cell lung cancer.
Conference abstract · 20 Sep 2018
Structure-Based Discovery of TRAF-STOPS: Small Molecule Inhibitors of the CD40-TRAF6 Interaction to block Inflammatory Pathways in Atherosclerosis and other Immune-Modulated Pathologies
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Khaled Barakat”
